Answers are grounded in this paper and cite their sources.
Phase I trial reveals manageable safety of BI 905711 in advanced gastrointestinal cancers, suggesting limited clinical benefit.
In heavily pretreated patients with GI tumors, BI 905711 monotherapy or with FOLFIRI plus bevacizumab displayed a manageable safety profile and limited clinical activity.
No takes yet. Share an insight, caveat, or question.
Harding et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: